The surfaces of the nanocarriers were designed with targeting ligands that can interact with tumor-specific receptors such as EGFR [52], folate receptor [53,54], and LHRH receptor [55,56], providing for a targeted delivery of anticancer medicines specifically to lung cancer cells, increasing their bioavailability and finally resulting in enhanced anticancer efficacy and limited adverse side effects upon healthy organs, tissues, and cells [21,22,57,58,59,60,61,62]. The gene discussed is EGFR; the disease is lung carcinoma.